Post-Authorisation Study on the Use of Bemfola® in Human Assisted Reproductive Technology
Status:
Completed
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
Prospective, non-comparative, multi-centre, multi-country, observational post-authorization
study, to correlate predictive factors with number of oocytes in relation to the gonadotropin
dose administered using a new r-hFSH product (Bemfola®) for ovarian stimulation and
GnRH-antagonists for pituitary suppression